Science Weekly Is there hope on the horizon for patients with Alzheimer’s?
25 snips
Sep 23, 2025 In this engaging discussion, Professor Jonathan Schott, a neurology expert from University College London, dives into groundbreaking research on diagnosing Alzheimer’s disease. He sheds light on a promising £100 blood test trial designed to revolutionize detection, emphasizing its significance for early and accurate diagnosis. Schott also examines the complexities of treatment options, including recent drug approvals and the impact of NICE’s cost-effectiveness evaluations. Listeners can gain hope as he explores innovative therapies aimed at overcoming this devastating disease.
AI Snips
Chapters
Transcript
Episode notes
Core Proteins Define Alzheimer’s
- Alzheimer's core hallmarks are abnormal beta-amyloid and phosphorylated tau proteins in the brain.
- Detecting these proteins is central to accurate diagnosis and targeting treatments.
Current Diagnosis Is Incomplete
- Traditional diagnosis using cognitive tests and MRI is only about 70% accurate.
- PET scans and lumbar punctures are more accurate but are expensive and used in only ~2% of UK patients.
Use Blood Tests In Memory Clinics First
- Offer the blood test to patients with mild cognitive impairment in memory clinics to refine diagnosis.
- Provide results in a controlled trial setting to assess impact on diagnosis accuracy and patient experience.